Quince Therapeutics Inc (QNCX) Stock Price, Quote & News

Company Profile

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 910 5717

Website: quincetx.com

Address:

611 Gateway Boulevard, Suite 273, South San Francisco, United States

Mmssmm Jul. 3 at 1:29 PM

$QNCX clearly true unfortunately

0 · Reply

iAm_Goatz Jul. 2 at 10:49 PM

$QNCX same sentiments. if you wanna turn every $10K of your hard earned money into $1,300, buy buy buy amd HODL for a few years 🤣🫠🕳️

0 · Reply

BullKing214 Jul. 2 at 8:26 PM

$QNCX will I ever be able to sell my options or exercise them. Keep getting corporate action warning. I’ve had them for months.

1 · Reply

Mmssmm Jul. 2 at 6:38 PM

$QNCX you realize that MF

0 · Reply

Mmssmm Jul. 2 at 6:36 PM

$QNCX very low free float No dilution by SEC what are you waiting for MF laziness??!! Take this stock very high to the moon

0 · Reply

Mmssmm Jul. 2 at 6:34 PM

$QNCX %100

0 · Reply

Mmssmm Jul. 2 at 6:29 PM

$QNCX Ultra low float 🔥 Only 977k shares No dilution locked 🔐 up $80 a share for 2 coverage And $100 for one coverage lifesci

0 · Reply

Mmssmm Jul. 2 at 5:45 PM

$QNCX take it to $80 a share MF

0 · Reply

StreakGeek Jul. 2 at 4:49 PM

$TRNR $QNCX nice guys

0 · Reply

Mmssmm Jul. 2 at 4:03 PM

$QNCX two really rare advantages rarely happen 1- very low free float 977k shares. 2 -company cannot dilute new shares because of the restrictions by SEC. So all traders and speculators this is the golden opportunity to make money 💰

0 · Reply

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

2026-06-29T23:50:11.000Z - 4 days ago

Quince Therapeutics trading halted, news pending

2026-06-24T10:35:33.000Z - 10 days ago

Quince Therapeutics initiated with an Outperform at Leerink

2026-06-23T13:39:25.000Z - 11 days ago

Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-06-23T10:12:54.000Z - 11 days ago

Quince Therapeutics initiated with an Overweight at Cantor Fitzgerald

May 18, 2026, 10:21 AM EDT - 6 weeks ago

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026, 10:00 AM EDT - 6 weeks ago

Quince Therapeutics Transcript: Investor update

May 18, 2026, 10:00 AM EDT - 6 weeks ago

Quince Therapeutics Press release: Investor update

May 18, 2026, 10:00 AM EDT - 6 weeks ago

Quince Therapeutics Slides: Investor update

2026-05-18T13:41:04.000Z - 6 weeks ago

Quince Therapeutics announces LAM-001 data

2026-05-18T13:35:06.000Z - 6 weeks ago

Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed

May 18, 2026, 9:26 AM EDT - 6 weeks ago

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026, 9:26 AM EDT - 6 weeks ago

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 17, 2026, 7:00 AM EDT - 6 weeks ago

Quince Therapeutics Slides: Investor presentation

May 11, 2026, 7:00 AM EDT - 7 weeks ago

Quince Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Quince Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Quince Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Quince Therapeutics Proxy statement: Proxy filing

2026-04-10T23:53:15.000Z - 3 months ago

Quince Therapeutics trading halted, news pending

Apr 10, 2026, 7:00 AM EDT - 3 months ago

Quince Therapeutics Annual report: Q4 2025

2026-03-30T12:54:26.000Z - 3 months ago

Quince Therapeutics settles $16.4M of debt

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Quince Therapeutics Settles Approximately $16.4 Million of Debt

Feb 9, 2026, 4:05 PM EST - 5 months ago

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives

Jan 29, 2026, 3:10 PM EST - 5 months ago

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

Jan 28, 2026, 4:05 PM EST - 5 months ago

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting

Dec 15, 2025, 8:00 AM EST - 7 months ago

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

Dec 10, 2025, 4:05 PM EST - 7 months ago

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

Dec 3, 2025, 10:30 AM EST - 7 months ago

Quince Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 7 months ago

Quince Therapeutics to Participate at Investor Events in December 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Quince Therapeutics Slides: Investor Presentation

Nov 12, 2025, 4:05 PM EST - 8 months ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:00 PM EST - 8 months ago

Quince Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 4:00 PM EST - 8 months ago

Quince Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 4:05 PM EST - 8 months ago

Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Oct 9, 2025, 4:05 PM EDT - 9 months ago

Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting

Oct 2, 2025, 10:00 AM EDT - 9 months ago

Quince Therapeutics Transcript: Investor Day 2025

Oct 2, 2025, 10:00 AM EDT - 9 months ago

Quince Therapeutics Slides: FY 2025

Sep 25, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study

Sep 15, 2025, 7:00 AM EDT - 10 months ago

Quince Therapeutics Slides: Investor Presentation

Sep 11, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics to Host Virtual Investor Day on October 2, 2025

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Quince Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Quince Therapeutics Slides: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 10 months ago

Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 11, 2025, 4:05 PM EDT - 11 months ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Quince Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 11 months ago

Quince Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

OPCH

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Registration statement: Registration Filing

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Jul 10, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Jun 25, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research Conference

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Quince Therapeutics Slides: Investor Presentation

Jun 18, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities

Jun 12, 2025, 5:15 PM EDT - 1 year ago

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Earnings release: Q1 2025

May 7, 2025, 3:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Citizens Life Sciences Conference

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 9, 2025, 8:00 AM EDT - 1 year ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Mar 24, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Earnings release: Q4 2024

Mar 24, 2025, 4:00 PM EDT - 1 year ago

Quince Therapeutics Annual report: Q4 2024

Feb 12, 2025, 2:00 PM EST - 1 year ago

Quince Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Transcript: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Press release: Investor Update

Feb 7, 2025, 10:00 AM EST - 1 year ago

Quince Therapeutics Slides: Investor Update

Feb 7, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Feb 5, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Jan 28, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Jan 27, 2025, 8:00 AM EST - 1 year ago

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

Jan 5, 2025, 6:00 PM EST - 1 year ago

Quince Therapeutics Slides: Investor Presentation

Dec 18, 2024, 7:00 AM EST - 1 year ago

Quince Therapeutics Registration statement: Registration Filing

Nov 13, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 6:00 PM EST - 1 year ago

Quince Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 6:00 PM EST - 1 year ago

Quince Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

Nov 11, 2024, 4:05 PM EST - 1 year ago

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Transcript: The ThinkEquity Conference 2024

Oct 30, 2024, 3:00 PM EDT - 1 year ago

Quince Therapeutics Slides: FY 2024

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Transcript: LD Micro Main Event XVII

Oct 29, 2024, 6:30 PM EDT - 1 year ago

Quince Therapeutics Slides: LD Micro Main Event XVII

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Participate at Upcoming Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Aug 13, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q2 2024

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 13, 2024, 1:30 PM EDT - 2 years ago

Quince Therapeutics Slides: The Citizens JMP Life Sciences Conference

May 13, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

May 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Quarterly report: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q1 2024

May 6, 2024, 4:05 PM EDT - 2 years ago

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Quince Therapeutics Proxy statement: Proxy Filing

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Mar 31, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Annual report: Q4 2023

Mar 31, 2024, 6:00 PM EDT - 2 years ago

Quince Therapeutics Earnings release: Q4 2023

Mar 26, 2024, 4:00 PM EDT - 2 years ago

Quince Therapeutics Transcript: Study Update

Feb 22, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Launches Scientific Advisory Board

Feb 15, 2024, 7:00 AM EST - 2 years ago

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Feb 7, 2024, 4:05 PM EST - 2 years ago

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Mmssmm Jul. 3 at 1:29 PM

$QNCX clearly true unfortunately

0 · Reply

iAm_Goatz Jul. 2 at 10:49 PM

$QNCX same sentiments. if you wanna turn every $10K of your hard earned money into $1,300, buy buy buy amd HODL for a few years 🤣🫠🕳️

0 · Reply

BullKing214 Jul. 2 at 8:26 PM

$QNCX will I ever be able to sell my options or exercise them. Keep getting corporate action warning. I’ve had them for months.

1 · Reply

Mmssmm Jul. 2 at 6:38 PM

$QNCX you realize that MF

0 · Reply

Mmssmm Jul. 2 at 6:36 PM

$QNCX very low free float No dilution by SEC what are you waiting for MF laziness??!! Take this stock very high to the moon

0 · Reply

Mmssmm Jul. 2 at 6:34 PM

$QNCX %100

0 · Reply

Mmssmm Jul. 2 at 6:29 PM

$QNCX Ultra low float 🔥 Only 977k shares No dilution locked 🔐 up $80 a share for 2 coverage And $100 for one coverage lifesci

0 · Reply

Mmssmm Jul. 2 at 5:45 PM

$QNCX take it to $80 a share MF

0 · Reply

StreakGeek Jul. 2 at 4:49 PM

$TRNR $QNCX nice guys

0 · Reply

Mmssmm Jul. 2 at 4:03 PM

0 · Reply

Mmssmm Jul. 2 at 3:53 PM

$QNCX take it to $80 a share Ultra low float Yes we can

0 · Reply

Mmssmm Jul. 2 at 3:49 PM

$QNCX hey lazy boys if we don’t get an advantage on low float 977k Then when we do??!!

0 · Reply

john4030 Jul. 2 at 3:04 PM

$LIMN I want to see a run like $QNCX did to nearly a dollar

0 · Reply

Mmssmm Jul. 2 at 2:33 PM

$QNCX pump it up MF

0 · Reply

Mmssmm Jul. 2 at 2:00 PM

$QNCX I think most of you here are shorty Interaction is zero 0️⃣

0 · Reply

Mmssmm Jul. 2 at 1:38 PM

$QNCX why the stock is frozen 🥶??!!

0 · Reply

Mmssmm Jul. 2 at 8:37 AM

$QNCX pump it up 🆙 🔝

0 · Reply

Mmssmm Jul. 2 at 6:46 AM

$QNCX new acquisition??!! Or Fast track FDA!!

0 · Reply

Mmssmm Jul. 2 at 4:33 AM

$QNCX they’re making it very low float 977k Now our job is to make it go very high like all low float stocks Why we’re lazy??!!

0 · Reply

JacksonHole Jul. 1 at 9:03 PM

$QNCX split city how many ? 3 ? 4 ?

0 · Reply

Ramanda87 Jul. 1 at 8:58 PM

$QNCX it F***** better be… I’ve been both patient and positive in my comments for a while now. But after the 20-1 RS we are looking at 85ct a share, and before that it was the 10-1 RS which makes this 8.5ct, Which is lower than where it was floating months ago after the crash between 10-35ct, and certainly lower than before the crash at $4-5 😡

0 · Reply

NicoG10 Jul. 1 at 5:55 PM

$QNCX news gotta be coming soon

1 · Reply

Market Cap	16.85M
Revenue (ttm)	0.00
Net Income (ttm)	-83.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	45,000
Avg Vol	65,351
Day's Range	N/A - N/A
Shares Out	978,000.00
Stochastic %K	41%
Beta	1.40
Analysts	Sell
Price Target	$86.67